Plunkett Research Online: Amicus Therapeutics Inc

AMICUS THERAPEUTICS INC (FOLD:NAS) Company Profile, Corporate Revenues, Growth, Market Size, Analysis, Business Forecasts, Market Share, Metrics, SWOT

Amicus Therapeutics, Inc. is a biotechnology company focused on the discovery, development and commercialization of novel treatments for rare diseases. The firm’s primary product is migalastat HC1, an oral precision medicine for people with Fabry disease who have amenable genetic mutations. Migala.....



Amicus Therapeutics Inc
Ticker: FOLD
Exchange: NAS
Parent Company:
Year Established:
Employees:
Fiscal Year Ends in

Phone: 609 662-2000
Fax: 609 662-2001
Address: 1 Cedar Brook Drive
Cranbury, NJ 08512 United States

Map
Types Of Business
Industry Ranks

Industry NAICS code:

Pharmaceutical Preparation Manufacturing
Contacts Description

John Crowley CEO/Chairman of the Board/Director
Daphne Quimi CFO
See More
Amicus Therapeutics, Inc. is a biotechnology company focused on the discovery, development and commercialization of novel treatments for rare diseases. The firm’s primary product is migalastat HC1, an oral precision medicine for people with Fabry disease who have amenable genetic mutations. Migala.....See More See More

Auditor: EY
Legal Advisor:
$USD, In whole numbers,
except marked * or %
2019 2018 2017 2016 2015 2014
Financials
    Revenue
    Cost of Revenue
    Gross Margin %
    R&D Expense
    Operating Income
    Operating Margin %
    SGA Expense
    Net Income
    Earnings Per Share
    Dividends
    Book Value Per Share
    Operating Cash Flow
    Capital Expenditure
    Free Cash Flow
Profitability
    EBITDA
    Return on Assets %
    Return on Equity %
    Net Margin %
    Assets Turnover
    Financial Leverage
Brands, Divisions and Affiliates Top Salaries
migalastat HC1
Galafold
Amicus Therapeutics GAA
Chaperone-Advanced Replacement Therapy
Name Title Salary (US$) Bonus (US$)
Other Thoughts Corporate Culture

Apparent Female Officers or Directors: